Gilenya and Tascenso ODT are approved to treat relapsing forms of multiple sclerosis (MS) in adults. Gilenya and Tascenso ODT ...

NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and safety in diverse patient populations. The MUSETTE trial confirmed that the ...

MS patients have increased risks of developing other autoimmune diseases, necessitating careful treatment planning to balance efficacy and risk. Dimethyl fumarate, anti-CD20 antibodies, and ozanimod ...

For people living with multiple sclerosis (MS), the search for effective treatment options can feel like a never-ending journey. While disease-modifying therapies (DMTs) have improved outcomes for ...

Modern disease-modifying drugs (DMTs) have revolutionized the treatment of relapsing-remitting multiple sclerosis (MS). However, their use during pregnancy has long been concerning. A study published ...

Scientists have identified two previously unknown biological subtypes of multiple sclerosis (MS) using artificial intelligence, a discovery that could help doctors tailor treatments more precisely to ...

Considering the CLARITY Phase III study results, cladribine tablets may offer several improvements over existing MS drugs including a simple, short-course annual dosing regimen of either 2 or 4 weeks ...